{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-009939","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.197490+00:00","generated_at":"2026-06-20T02:13:00.675168+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sesen Bio discloses ~$0.34/shr special dividend, 25.2% stake in combined company in Carisma merger","bullets":["Expected one-time cash dividend of ~$70M ($0.34/shr) upon merger close; plus CVR up to $0.14/shr from legacy asset sales and Roche milestone.","Sesen Bio stockholders to own 25.2% of combined company valued at $357M, led by Carisma management.","Board conducted 4-month strategic review, contacted 100+ parties, received 42 bids; determined merger maximizes value vs dissolution.","In dissolution scenario, estimated initial distribution only $0.40-$0.60/shr, available after 6+ months, full process up to 3 years.","Special stockholder meeting on March 2, 2023; Sesen Bio urges vote 'FOR'."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-009939","json":"https://secwatch.observer/filing/0001104659-23-009939.json","markdown":"https://secwatch.observer/filing/0001104659-23-009939.md","text":"https://secwatch.observer/filing/0001104659-23-009939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923009939/0001104659-23-009939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923009939/tm235275d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T02:13:00.675168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}